+49 (0) 162 2343 600 | E-Mail: info@healthcareshapers.com
  • LANGUAGES
    • Deutsch Deutsch
    • English English
    • Français Français

Healthcare Shapers

  • About us
  • Clients
  • Contact
  • Services
  • Collaborators
  • Blog
  • News
 31. January 2023

Month: March 2018

Successfully developing the German market with orphan drugs and new products

Thursday, 29 March 2018 by Dr. Carsten von Blohn
Market_Entry_Germany_Healthcareshapers_com

The day of rare diseases on February 28 focussed attention once again this year on the high unmet medical need in view of the 6,000 to 8,000 ‘rare’ or ‘orphan diseases’ for which there are until now no comprehensive therapies.1 The summary of the medicines newly approved in 2017 in Germany may mark an advance with 9 of 31 orphan drugs in this regard.2 The potential for innovative foreign companies, however, is evident – combined with the fact that a market entry in Germany is critical for success at the European level, it is logical for start-ups in particular to take the German market into consideration as their first choice for an expansion. A successful concept for this will include both organizational and market-specific aspects.

Orphan drugs, in addition to other therapeutic agents, provide a good example of business ideas with a potential for expansion. That’s because those who are working in the area of orphan diseases are researching at the forefront: many rare diseases are genetically determined, and scientists need to make use of molecular biology methods to clarify the disease mechanisms.3 The corresponding medicinal products are not infrequently developed by start-ups based in the USA.

After market launch in the United States, the second step is to develop markets in Europe. Due to Germany’s size as well as its relatively rapid reimbursement, many such companies consider the country an attractive initial target market. The lessons learned in Germany can then be transferred to other European countries.

Laying the foundations depending on company size and requirements: organizationally, structurally, close to the market

In a market expansion, foreign companies are confronted with numerous internal and external challenges. In particular, newly established companies lack the functional and specialist resources that an established player has from the outset. A network of competent, independent service providers with different specializations provides a powerful and at the same time cost-effective solution to creating the organizational and structural conditions for successful establishment in Germany and launch of the products.

At the company level, the first steps include searching for a suitable location and setting up a subsidiary, for instance a capital company. Decisions also need to be made on the topics of distribution and logistics. The latter can pose a great challenge in gene therapies. Besides regulations under finance and labor law, there are specific topics for the pharmaceutical industry when founding a company: for instance, establishing pharmacovigilance, appointing information officers, creating approval procedures, or generating a wholesale license.

The product-specific and market-specific challenges with which even established players are confronted when launching a product in Germany consist mainly of a profound understanding of the market when deriving a launch strategy, and bringing about a successful product launch. Once the market mechanisms, treatment guidelines and relevant stakeholders are known, it is easier for companies to develop market access and price strategies and address the right target groups – from medical specialist groups to patient organizations to public health policy.

The time required and the complexity of these tasks are often underestimated. At the same time, the individuals responsible are making decisions with a great scope, decisions are then difficult to revise. Whether for orphan drugs or other new products: for companies abroad of varying sizes, collaborating with cross-functional teams of local consultants is worthwhile for successful entry into the German market.

Sources:
1https://www.rarediseaseday.org/country/de/germany
2https://www.vfa.de/de/presse/pressemitteilungen/pm-028-2017-bilanz-2017-fortschritte-durch-neue-arzneimittel.html
3https://www.vfa-bio.de/vb-de/aktuelle-themen/orphans/immer-mehr-patienten-mit-seltenen-erkrankungen-behandelbar.html

Market EntryOrphan DrugsProduct Launch
Read more
  • Published in Market Access, Uncategorized
No Comments

Suche

Letzte Beiträge

  • Strategie trifft Umsetzung

    Driving the Strategy Execution

    In our complex and busy world, a lot of focus i...
  • Faster time to market, less funds: How to survive as a BioTech Startup?

    Faster time to market, less funds: How to survive as a BioTech Startup?

    The climate of overall uncertainty in markets i...
  • Building vs. Breaking Mental Health with Digital Technology

    Healthcare Shapers Perspectives Guest: Craig A....
  • From Crisis to Clarity

    Healthcare Shapers Perspectives Guest: Kathy Le...
  • 3 Essential Strategies To Healthcare Commercial Success

    Healthcare Shapers Perspectives Guest: Erkan Ha...

Archiv

  • January 2023
  • August 2022
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • April 2020
  • March 2020
  • December 2019
  • September 2019
  • November 2018
  • March 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • August 2017
  • July 2017
  • May 2017
  • April 2017

Kategorien

  • digitalization
  • e-health
  • Innovative Care
  • leadership
  • Market Access
  • Mobile
  • patient-centricity
  • Perspectives
  • Strategy
  • Technology
  • Telehealth
  • Uncategorized
  • Virtual Reality

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org

Empfohlen

  • Strategie trifft Umsetzung

    Driving the Strategy Execution

    0 comments
  • Faster time to market, less funds: How to survive as a BioTech Startup?

    Faster time to market, less funds: How to survive as a BioTech Startup?

    0 comments
  • Building vs. Breaking Mental Health with Digital Technology

    0 comments
  • From Crisis to Clarity

    0 comments
  • 3 Essential Strategies To Healthcare Commercial Success

    0 comments

NAVIGATION

  • About us
  • Clients
  • Contact
  • Services
  • Collaborators
  • Blog
  • News

NEWSLETTER

Enter your e-mail address and we will gladly keep you informed about current topics and upcoming events.

RSS-Feed abonnierenRSS-Feed abonnieren

HEALTHCARE SHAPERS

Günther Illert
(Founder of the network)
Rheingauer Straße 49c
D-65343 Eltville
Germany

M +49 (0) 162 2343 600

E-Mail:info@healthcareshapers.com

  • About us
  • Contact
  • Site Notice
  • Privacy Policy
  • GET SOCIAL

Healthcare Shapers© 2018 All rights reserved.

TOP
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies. Read More
Cookie settingsACCEPT
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT